Novo Nordisk Investigational Site

Cambridge CB3 8RE

0 studies enrolling now · 10 studies all time

What they study most

Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass, Chronic Kidney Disease, Diabetes, Diabetes Mellitus, Type 1, End-Stage Renal Disease, Haemophilia A, Haemostasis, Hepatobiliary Disorders, Metabolism and Nutrition Disorder, Non-alcoholic Steatohepatitis, Obesity

Studies at this site

• STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity — Completed
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. — Completed
• A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors — Completed
• Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus — Completed
• Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes — Completed
• Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes — Completed
• Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery — Completed
• The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis — Stopped early
• Use of Activated Recombinant Human Factor VII in Cardiac Surgery — Stopped early
• Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass — Completed